Purpose of review: This article reviews multiple secondary and primary prevention trials that have expanded the indications for implantable cardioverter-defibrillators (ICDs). Recent findings: Most studies performed over the last several years have concentrated on the role of ICDs in high-risk patients for the primary prevention of sudden death. Several recent trials that have been completed but not published are also reviewed. Summary: Data from recently completed trials and evolving ICD technology, such as ICDs with cardiac resynchronization capabilities, will alter indications for ICDs in the near future.
|Number of pages
|Current Opinion in Cardiology
|Published - Jul 1 2004
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine